Eli Lilly is set to supply 388,000 doses of its Covid-19 neutralising antibody therapy, etesevimab, to the US Government. This drug will complement bamlanivimab doses that the government previously acquired from the company. Lilly will ship nearly 200,000 doses of etesevimab in the third quarter of 2021 and the remaining doses in the fourth quarter. The company estimates the latest deal will be worth around $330m in revenue in the second half of the year.
Moderna has reported new data from the Phase III COVE clinical trial of its Covid-19 vaccine which showed that the shot’s protection wanes over time, arguing that this supports the need for a booster dose to sustain high protection levels. The company noted that the vaccine has maintained its effectiveness even amid the delta variant surge, but subjects who were inoculated more recently were less likely to experience a breakthrough infection versus those vaccinated last year.
Russia’s state-owned sovereign wealth fund, the Russian Direct Investment Fund (RDIF), has reported that the country’s Sputnik V Covid-19 vaccine demonstrated 97.2% efficacy and a strong safety profile according to real-world data gathered during a vaccination campaign in the Republic of Belarus. This efficacy against Covid-19 was analysed based on findings from over 860,000 individuals vaccinated between January and July this year. The vaccine was not associated with any severe adverse events or deaths, according to the RDIF.